SynthesisHeart failure reviews2020
Cost-effectiveness analysis of PCSK9 inhibitors in cardiovascular diseases: a systematic review.
Synthesis in Heart failure reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Early administration of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with acute coronary syndrome: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Is a PCSK9 Inhibitor Right for Your Patient? A Review of Treatment Data for Individualized Therapy.International journal of environmental research and public health · 2022Pooled it
- Pooled it
- Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.PharmacoEconomics · 2020Pooled it
- Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.Cardiovascular drugs and therapy · 2026Review
- Article
- Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data.Journal of the American Heart Association · 2026Article
- Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study.Healthcare (Basel, Switzerland) · 2025Article
- Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.Diseases (Basel, Switzerland) · 2024Article
- Proprotein convertase subtilisin/kexin type 9 inhibitors in peripheral artery disease: A review of efficacy, safety, and outcomes.World journal of cardiology · 2024Review
- Broader Perspective on Atherosclerosis-Selected Risk Factors, Biomarkers, and Therapeutic Approach.International journal of molecular sciences · 2024Review
- First Iranian guidelines for the diagnosis, management, and treatment of hyperlipidemia in adults.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Article
- Cost Effectiveness Analysis Rivaroxaban Plus Aspirin versus Aspirin alone in Treatment Cardiovascular Diseases: A Systematic Review.Medical journal of the Islamic Republic of Iran · 2024Review
- In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show?Current atherosclerosis reports · 2023Review
- Inclisiran: A Review in Hypercholesterolemia.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2023Review
- Management of High-Risk Hypercholesterolemic Patients and PCSK9 Inhibitors Reimbursement Policies: Data from a Cohort of Italian Hypercholesterolemic Outpatients.Journal of clinical medicine · 2022Article
- Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.Clinical drug investigation · 2022Article
- New Treatment Targets and Innovative Lipid-Lowering Therapies in Very-High-Risk Patients with Cardiovascular Disease.Biomedicines · 2022Review
- Cost-Effectiveness Analysis of Evolocumab for the Treatment of Dyslipidemia in the Kingdom of Saudi Arabia.PharmacoEconomics - open · 2022Article
- Lipid-Lowering Drug Therapy: Critical Approach for Implementation in Clinical Practice.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess the cost-effectiveness of pro-protein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in cardiovascular disease. METHODS AND
resultsWe performed a comprehensive search strategy in electronic databases from January 2015 to January 2019. Out of 475 articles, 16 were entered into the study. Quality-adjusted life year, life years gained (LYG), annual cost, and the incremental cost-effectiveness ratio (ICER) regarding the use of PCSK9 inhibitors were considered as the key outcomes. The cost-effectiveness threshold varied from $45,000 in Spain to $150,000 in the USA. The annual cost of PCSK9 inhibitors for studies undertaken in the USA was in the range of $14,000 to $15,000, while it was about $7000 for other developed countries. The results showed that reduction in the price of PCSK9 inhibitors changed from 20 to 88%. The means of QALY were 0.65 and 0.67 in the Markov and Cardiovascular Disease Policy Modeling (CVDPM) models; also, the ICER means were $197,707 and $625,555 for the Markov and CVDPM model, respectively.
conclusionAccording to the current study, the effectiveness of PCSK9 inhibitors is well documented, although all studies pointed out a higher cost of these inhibitors.
trial registrationThis study was registered within the International Prospective Register of Systematic Reviews (PROSPERO) database of the University of York (CRD42018088472).
Indexed as
Identifiers
31832834What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.